JAMA Network December 13, 2023
The US Food and Drug Administration has yet to approve any drugs for preventing or treating post–COVID-19 condition, also known as long COVID—defined by the US government as health issues that continue or develop 4 weeks or more after an initial SARS-CoV-2 infection. But 2 recent observational studies took a close look at whether existing antiviral treatments for COVID-19 may protect against developing long COVID down the line.
“Overall, any preventive measures (like vaccines) or treatments that decrease the severity of acute COVID are likely to lead to reduced risk of persistent symptoms,” Benjamin Abramoff, MD, MS, an assistant professor of clinical physical medicine and rehabilitation at the University of Pennsylvania, told JAMA in an email.
A Research Letter published...
Today's Sponsors
Today's Sponsor